SO-10 An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway

Autor:	M. Jung, C. Kim, H. Kim, C. Lee, H. Lee, W. Bae, H. Jeung, D. Zang, S. Park, I. Hwang, S. Rha, H. Chung
Rok vydání:	2021
Předmět:	business.industry Hematology Advanced gastric cancer chemistry.chemical_compound Oncology Paclitaxel chemistry Cancer research Medicine In patient Open label Multi centre business PI3K/AKT/mTOR pathway
Zdroj:	Annals of Oncology. 32:S206
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.05.034
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::71690d3b11088f59e1a167acb36a7f2b https://doi.org/10.1016/j.annonc.2021.05.034 Zobrazit plný text záznamu